Navigation Links
Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
Date:12/4/2008

Partnership will accelerate research of potential vaccine for low-resource countries

SEATTLE, and GAITHERSBURG, Md., Dec. 4 /PRNewswire/ -- The biotech company Lentigen Corporation and the nonprofit global health organization PATH announced today a partnership to accelerate research on a pandemic influenza vaccine. PATH will initially invest $3 million over 27 months and work with Lentigen on early-stage development of a H5N1 virus-like particle (VLP) prototype pandemic influenza vaccine.

With global health leaders increasingly concerned about the possibility of an influenza pandemic, PATH is working with public- and private-sector partners to advance the development of new, safe, and effective influenza vaccines that can be produced quickly and economically in large quantities to combat a global influenza pandemic, especially in low-income countries.

Vaccines based on VLPs can overcome many of the limitations of traditional influenza vaccines by offering highly immunogenic, strain-specific recombinant antigens that can be produced economically and at large scale. VLPs are self-assembling particles that can be made in cell culture, avoiding the need to rely on limited egg supplies for vaccine production. The Lentigen process may have unique advantages by producing high yields of VLPs in a portable and disposable manufacturing system.

"We are delighted to partner with Lentigen," commented Dr. Kathleen Neuzil, director of PATH's Influenza Vaccine Development Project. "Lentigen's technology is versatile and economical, and could be transferred to manufacturers in multiple locations to achieve our goal of developing a pandemic influenza vaccine to meet the needs of people in low-resource countries."

"The rapid development, production, and distribution of pandemic influenza vaccines could potentially save millions of lives in parts of the world that may not otherwise have access to an effective vaccine," noted Tim Ravenscroft, CEO of Lentigen. "We are excited to be working with PATH and applying Lentigen's VLP technology to combat one of the major infectious disease threats to the human population."

PATH is pursuing multiple vaccine strategies that could produce much greater quantities of vaccine at a price affordable in developing countries. In addition to helping with pandemic preparedness, new vaccines could also address the high burden of annual or seasonal influenza, which annually causes between three and five million cases of severe illness and up to 500,000 deaths worldwide.

About PATH

PATH is an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health. By collaborating with diverse public- and private-sector partners, PATH helps provide appropriate health technologies and vital strategies that change the way people think and act. PATH's work improves global health and well-being. For more information, please visit www.path.org.

About Lentigen Corporation

Lentigen Corporation is a privately owned diversified biologics company focused on the development and commercialization of breakthrough treatments for human disease. The company's development programs, which are based on its proprietary lentiviral RNA delivery technology, include novel cell, vaccine, and protein therapeutics. Lentigen manufactures and supplies research products based on this technology to the academic, government, and biopharmaceutical research communities through its collaborations with ThermoFisher Scientific and Invitrogen. Lentigen has a broad range of research collaborations including those with the US National Institutes of Health, the University of Pennsylvania, Case Western Reserve University, Emory University, and the US Army. For further information, please visit www.lentigen.com.

    Contacts:

    PATH
    Eileen Quinn
    202-454-5005
    equinn@path.org

    Richard Lewis Communications, Inc.
    212-827-0020
    Megan Dubrowski (Media)
    mdubrowski@rlcinc.com
    Cecelia Heer (Investors)
    cheer@rlcinc.com


'/>"/>
SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lentigen Corporation Announces Relocation to New Facility
2. Lentigen Appoints Jim Meade as Vice President of Corporate Development
3. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
4. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
5. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
6. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
7. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
8. VIRxSYS and Lentigen Announce Litigation Settlement
9. Met-Pro Corporation Declares Quarterly Dividend
10. China Medicine Corporation Awarded GSP Certification
11. Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... and WASHINGTON , March 28, ... provider, GENEWIZ, will launch single-cell sequencing during the American Association ... E. Washington Convention Center in Washington, D.C. ... to perform differential gene expression of thousands of cells ... Experts on-hand at AACR ...
(Date:3/28/2017)... , March 28, 2017 Dr. ... international life sciences corporation Anpac Bio-Medical Science ... a new, international record, processing and reporting over ... "Cancer Differentiation Analysis" (CDA) liquid biopsy tests. ... Nobel Prize Laureate Summit publications, Anpac Bio,s CDA ...
(Date:3/28/2017)... , March 28, 2017 ... and unpredictable sector due to the scientifically intensive ... include medical, agricultural, environmental, and industrial. In today,s pre-market ... Portola Pharmaceuticals Inc. (NASDAQ: PTLA), OvaScience Inc. (NASDAQ: ... Therapeutix Inc. (NASDAQ: OCUL ). Learn ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Harvill as Chief Executive Officer with Avomeen Analytical Services. Harvill is a distinguished ... and operations. , Avomeen is a leader in a wide range of ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant ... At PTE ... March, Materna will present its complete end-to-end passenger journey, ... real benefit for passengers. To accelerate the whole passenger handling ... solutions to take passengers through the complete integrated process with ...
Breaking Biology News(10 mins):